Search

Your search keyword '"van Meerten, Esther"' showing total 44 results

Search Constraints

Start Over You searched for: Author "van Meerten, Esther" Remove constraint Author: "van Meerten, Esther" Search Limiters Full Text Remove constraint Search Limiters: Full Text
44 results on '"van Meerten, Esther"'

Search Results

2. The views of cancer patients of Turkish, Moroccan, Surinamese, and Dutch-Caribbean descent on diagnosis, treatment and prognosis:A systematic literature review

3. Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases:Protocol of the multicentre, open-label, phase II, INTERACT-II trial

4. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6)

5. Irinotecan-Induced Toxicity:A Pharmacogenetic Study Beyond UGT1A1

6. HYpofractionated, dose-redistributed RAdiotherapy with protons and photons to combat radiation-induced immunosuppression in head and neck squamous cell carcinoma:study protocol of the phase I HYDRA trial

7. ASO Visual Abstract:Treatment and Survival Outcomes of Patients with Colorectal Peritoneal Metastases Deemed Ineligible for Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Results of a Retrospective Study

8. Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies

9. Post radiation mucosal ulcer risk after a hypofractionated stereotactic boost and conventional fractionated radiotherapy for oropharyngeal carcinoma

10. ASO Visual Abstract

11. Genome-Wide Analyses of Nephrotoxicity in Platinum-Treated Cancer Patients Identify Association with Genetic Variant in RBMS3 and Acute Kidney Injury

12. Fewer head and neck cancer diagnoses and faster treatment initiation during COVID-19 in 2020: A nationwide population-based analysis: Impact of COVID-19 on head and neck cancer

13. Fewer head and neck cancer diagnoses and faster treatment initiation during COVID-19 in 2020:A nationwide population-based analysis: Impact of COVID-19 on head and neck cancer

14. Genome-Wide Analyses of Nephrotoxicity in Platinum-Treated Cancer Patients Identify Association with Genetic Variant in RBMS3 and Acute Kidney Injury

16. Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial

17. Safety and Feasibility of Additional Tumor Debulking to First-Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer

18. Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin : Protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial

19. Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: Protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial

20. Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin:Protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial

21. Survival of patients with head and neck cancer with metachronous multiple primary tumors is surprisingly favorable

22. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parralel-group, phase II-III, randomised, superiority study (CAIRO6)

23. Genetic Variants as Predictive Markers for Ototoxicity and Nephrotoxicity in Patients with Locally Advanced Head and Neck Cancer Treated with Cisplatin-Containing Chemoradiotherapy (The PRONE Study)

25. Genetic Variants as Predictive Markers for Ototoxicity and Nephrotoxicity in Patients with Locally Advanced Head and Neck Cancer Treated with Cisplatin-Containing Chemoradiotherapy (The PRONE Study)

26. Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine

27. The CARTS study: Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery

28. Pharmacokinetics of Sublingually Delivered Fentanyl in Head and Neck Cancer Patients Treated with Curatively Aimed Chemo or Bioradiotherapy

29. Pharmacokinetics of sublingually delivered fentanyl in head and neck cancer patients treated with curatively aimed chemo or bioradiotherapy

30. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands

31. Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults

32. Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults

33. Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults

34. Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases:the CHARISMA randomized multicenter clinical trial

35. Response to chemotherapy in patients with recurrent rectal cancer in previously irradiated area

36. Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial

38. Chemoradiation for advanced hypopharyngeal carcinoma: a retrospective study on efficacy, morbidity and quality of life

39. Combined therapy for thyroid squamous cell carcinoma

40. The CARTS study: Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery

41. Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases: protocol of the multicentre, open-label, phase II, INTERACT-II trial.

42. Safety and Feasibility of Additional Tumor Debulking to First-Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer.

43. Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial.

44. Phase I study of cisplatin, hyperthermia, and lapatinib in patients with recurrent carcinoma of the uterine cervix in a previously irradiated area.

Catalog

Books, media, physical & digital resources